Repare Therapeutics

Today at the ESMO - European Society for Medical Oncology Gastrointestinal Cancers Congress 2024, we're presenting positive new data from our MINOTAUR clinical trial combining lunresertib with FOLFIRI. Learn more here: https://lnkd.in/eFtdwSJV #precisiononcology #clinicaltrials #syntheticlethality

Thank you to the National Cancer Institute (NCI) for highlighting Repare Therapeutics' investigation of camonsertib, guided by the Oncology Center of Excellence's Project Optimus to optimize dose and schedule. We are grateful to our study team - nurses, study coordinators and investigators - for their close monitoring and dedication in the development of camonsertib. Learn more here: https://lnkd.in/eBgYzP3b #precisiononcology #clinicaltrials

CONFERENCE UPDATE: The abstract is available for Repare Therapeutics' presentation at ESMO GI from the Phase 1 MINOTAUR trial evaluating lunresertib in combination with FOLFIRI. Learn more here: https://lnkd.in/ebPvugmb #precisiononcology #syntheticlethality #clinicaltrials

Precision Oncology in Quebec - from laboratory to patient.....precisely! Repare Therapeutics is hosting a Precision Oncology Symposium on June 19, from 10 a.m. to 1 p.m. at the adMare BioInnovations Innovation Center in Montreal. Learn how our drug discovery efforts translate into biomarker-selected clinical trials, and hear from patients through their very personal experiences of fighting cancer. This is a rare opportunity to learn about the entire spectrum of oncology, with panelists from the lab to clinical development to the patient, with a particular focus on the importance of using NGS to deliver the right drug to the right patient. Although it is now full, the event is open to stakeholders from the life sciences industry, universities, hospitals and government interested in learning more about what the future of precision oncology looks like in Quebec. Details here: https://lnkd.in/eETDeYVX #precisiononcology #clinicaltrials #syntheticlethality

Please join Repare Therapeutics in welcoming Dr. Steven H. Stein to our Board of Directors, effective June 17, 2024. Dr. Stein currently serves as the Chief Medical Officer of Incyte Corporation, a position he has held since March 2015. Prior to joining Incyte, Dr. Stein has held leadership positions at Novartis Oncology, GlaxoSmithKline, and Kura Oncology. He has authored more than 100 scientific papers and presentations and is an Adjunct Assistant Professor in the University of Pennsylvania School of Medicine.

That's a wrap! Thank you to conference organizers and attendees for hosting and engaging with Repare Therapeutics at the AACR Journals Special Conference in Cancer Research: Expanding and Translating Cancer Synthetic Vulnerabilities and Goldman Sachs 45th Annual Global Healthcare Conference this week.

We are collaborating with Foundation Medicine to deliver genomic profiling to patients in our lunresertib clinical trials and beyond. We are thrilled to take this next step with the global leader in companion diagnostic approvals for next generation sequencing testing, with the potential to develop a companion diagnostic and expand access to clinical trial sites for our global lunresertib program. Learn more here: https://lnkd.in/enRH_8eA #precisiononcology #clinicaltrials #companiondiagnostic #PKMYT1inhibition

Join Repare Therapeutics’ management team in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami. Check out our webcast to hear the latest updates: https://lnkd.in/eKbrQQfq #syntheticlethality #clinicaltrials $RPTX

The first patient has been treated in Repare Therapeutics' camonsertib monotherapy expansion in ATM-mutated non-small cell lung cancer. We are grateful to our patients, investigators, and team who share in our mission to bring therapies to patients in need. Learn more here: https://lnkd.in/eESd9yaN #precisiononcology #clinicaltrials #NSCLC

We are thrilled to share that the FDA granted Fast Track designation to the lunresertib-camonsertib combination for the treatment of platinum-resistant ovarian cancer. Learn more here: https://lnkd.in/e5n8Acxn #precisiononcology #syntheticlethality #fasttrackdesignation #ovariancancer